- Home
- BCSF vs MLYS Comparison
BCSF vs MLYS Comparison
Compare BCSF & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCSF
- MLYS
- Stock Information
- Founded
- BCSF 2015
- MLYS 2019
- Country
- BCSF United States
- MLYS United States
- Employees
- BCSF N/A
- MLYS N/A
- Industry
- BCSF Finance/Investors Services
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- BCSF Finance
- MLYS Health Care
- Exchange
- BCSF Nasdaq
- MLYS Nasdaq
- Market Cap
- BCSF 1.0B
- MLYS 1.0B
- IPO Year
- BCSF 2018
- MLYS 2023
- Fundamental
- Price
- BCSF $15.25
- MLYS $14.54
- Analyst Decision
- BCSF Buy
- MLYS Strong Buy
- Analyst Count
- BCSF 2
- MLYS 4
- Target Price
- BCSF $16.50
- MLYS $27.00
- AVG Volume (30 Days)
- BCSF 280.0K
- MLYS 862.9K
- Earning Date
- BCSF 08-05-2025
- MLYS 08-12-2025
- Dividend Yield
- BCSF 11.09%
- MLYS N/A
- EPS Growth
- BCSF N/A
- MLYS N/A
- EPS
- BCSF 1.75
- MLYS N/A
- Revenue
- BCSF $284,993,000.00
- MLYS N/A
- Revenue This Year
- BCSF N/A
- MLYS N/A
- Revenue Next Year
- BCSF N/A
- MLYS N/A
- P/E Ratio
- BCSF $8.73
- MLYS N/A
- Revenue Growth
- BCSF N/A
- MLYS N/A
- 52 Week Low
- BCSF $13.20
- MLYS $8.24
- 52 Week High
- BCSF $19.21
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- BCSF 49.09
- MLYS 47.97
- Support Level
- BCSF $14.88
- MLYS $13.22
- Resistance Level
- BCSF $15.17
- MLYS $14.54
- Average True Range (ATR)
- BCSF 0.25
- MLYS 0.71
- MACD
- BCSF 0.01
- MLYS 0.00
- Stochastic Oscillator
- BCSF 53.74
- MLYS 68.37
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.